Sun Pharmaceutical Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended 30 September 2026

Sun Pharmaceutical Industries Limited SUN HOUSE, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 14 October 2026 National Stock Exchange of India Limited BSE Limited NSE Code: SUNPHARMA Stock Code: 524715 Intimation under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Board Meeting and connected matters Board Meeting This is to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, 30 October 2026, inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended 30 September 2026. Trading Window Closure Further to our communication dated 25 September 2026, the Trading Window for dealing in the securities of the Company has been closed with effect from Thursday, 1 October 2026, and shall remain closed until 48 hours after the declaration of the aforesaid financial results, i.e., up to and including Sunday, 1 November 2026. For Sun Pharmaceutical Industries Limited (Anoop Deshpande) Company Secretary and Compliance Officer ICSI Membership No.: A23983 Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA Reaching People. Touching Lives